TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

Leukemia. 2008 Sep;22(9):1790-2. doi: 10.1038/leu.2008.56. Epub 2008 Mar 20.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Proliferation / drug effects
  • Erythroid Cells / pathology*
  • Humans
  • Janus Kinase 2 / antagonists & inhibitors
  • Janus Kinase 2 / genetics
  • Mutation
  • Myeloproliferative Disorders / drug therapy*
  • Myeloproliferative Disorders / genetics*
  • Myeloproliferative Disorders / pathology
  • Pyrrolidines / pharmacology*
  • Receptors, Thrombopoietin / genetics
  • Sulfonamides / pharmacology*
  • Tumor Cells, Cultured

Substances

  • Pyrrolidines
  • Receptors, Thrombopoietin
  • Sulfonamides
  • MPL protein, human
  • Fedratinib
  • JAK2 protein, human
  • Janus Kinase 2